Medtronic plc — Form 10-K Summary
Reporting period: Fiscal year ended April 24, 2020 (52 weeks), filed June 19, 2020. The filing is an FY2020 annual report, not a standalone 2019 fourth-quarter filing; it does provide Q4 results. All dollar amounts are in U.S. dollars.
Business context and period
Medtronic is a global medical technology company operating in more than 150 countries. Its four reportable groups are Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes. COVID-19 disrupted procedure volumes, customer purchasing, supply chains, clinical trials, and product launches, particularly in the fiscal fourth quarter.
Key financial metrics
| Metric | FY2020 | FY2019 | Change / context |
|---|---|---|---|
| Net sales | $28.913 billion | $30.557 billion | Down 5% |
| Operating profit | $4.791 billion | $6.268 billion | Down 24%; operating margin about 16.6% versus 20.5% |
| Net income attributable to Medtronic | $4.789 billion | $4.631 billion | Up 3% |
| GAAP diluted EPS | $3.54 | $3.41 | Up 4% |
| Non-GAAP diluted EPS | $4.59 | $5.22 | Down 12% |
| Operating cash flow | $7.234 billion | $7.007 billion | Up $227 million |
| Free cash flow | $6.021 billion | $5.873 billion | Up $148 million; company-defined non-GAAP measure |
| Cash and current investments | $10.948 billion | $9.848 billion | At fiscal year-end |
| Total debt | $24.8 billion | $25.3 billion | Includes $2.8 billion current and $22.0 billion long-term debt |
| Dividends declared per share | $2.16 | $2.00 | Up 8% |
FY2020 GAAP income tax benefit was $751 million, including approximately $1.2 billion of favorable tax adjustments. This materially boosted reported GAAP earnings; non-GAAP EPS, which excludes specified items, declined. Gross profit was $19.489 billion, or approximately 67.4% of sales, compared with approximately 70.0% in FY2019. These margins are calculated from reported sales and cost of products sold.
Fiscal Q4 sales were $5.998 billion versus $8.146 billion a year earlier; net income attributable to Medtronic was $646 million versus $1.172 billion, and diluted EPS was $0.48 versus $0.87.
Material changes versus FY2019
- All four groups reported lower annual sales: Cardiac and Vascular down 9% to $10.468 billion; Minimally Invasive Therapies down 1% to $8.352 billion; Restorative Therapies down 6% to $7.725 billion; and Diabetes down 1% to $2.368 billion.
- COVID-related procedure declines and changed customer buying patterns drove much of the fourth-quarter weakness. Respiratory, Gastrointestinal, and Renal sales rose 4%, supported by demand for ventilators, airway products, patient monitoring, and renal-care products.
- Operating profit fell despite lower selling, general, and administrative expense, as revenue contracted and the company incurred pandemic-related costs, higher restructuring expense, and increased litigation charges.
- Interest expense decreased to $1.092 billion from $1.444 billion, although FY2020 included $413 million of debt-tender and early-redemption charges.
- Cash flow from operations increased, while cash and cash equivalents declined by $253 million during the year. Capital spending was $1.213 billion.
Outlook, commentary, risks, and unusual items
- COVID-19 outlook: Management reported early signs of procedure recovery in some geographies as of the filing date, but expected recovery to vary by therapy and country. It could not predict the pandemic’s duration or severity and warned of continued effects on sales, cash collections, supply, hospitals’ spending, launches, and clinical development. No numerical FY2021 earnings or sales guidance is provided in the supplied filing text.
- Liquidity and capital allocation: Management said available liquidity was sufficient for foreseeable operating needs. The company had an undrawn $3.5 billion revolving credit facility and no public debt maturing until March 2021. It paused/deprioritized share repurchases amid COVID-19 while continuing its dividend. Subsequent to year-end, Medtronic borrowed approximately $2.8 billion under a six-month term loan, with an option to extend for six months.
- Restructuring: The Enterprise Excellence program targets more than $3.0 billion of annual gross savings by the end of FY2022, with expected annual savings of $500–$700 million through FY2022. Estimated pre-tax charges are $1.6–$1.8 billion, with cash outlays expected to be substantially complete by FY2023.
- Significant unusual items: Tax benefits included a $658 million release of a valuation allowance and a $269 million benefit related to an intercompany intellectual-property transfer, among other adjustments. FY2020 also included $313 million of certain litigation charges and an $80 million Medtronic Foundation contribution.
- Contingencies: Accrued litigation was approximately $0.5 billion. Major exposures include pelvic-mesh claims, a hernia-mesh lawsuit docket for which losses were not then probable or estimable, patent and commercial disputes, and environmental proceedings. The IRS dispute over income allocation involving Puerto Rico manufacturing remains unresolved; the 2005–2006 tax-court proceeding was postponed, and the company reported $1.862 billion of gross unrecognized tax benefits.
- Other risks: Medical-device regulation and product quality, competitive and reimbursement pressure, reliance on certain suppliers and manufacturing sites, currency movements, cybersecurity and privacy, acquisition integration, and international trade and tax changes may affect results.
Most important facts for investors to verify
- Whether procedure volumes and sales recovered after year-end, and how pandemic-related effects developed in FY2021.
- How much of FY2020’s GAAP earnings increase depended on tax benefits, versus underlying operating performance; review the non-GAAP reconciliations and recurring adjustments.
- Progress toward the Enterprise Excellence savings targets, remaining restructuring charges, and expected cash costs.
- Debt maturities, post-year-end borrowing and repayments, and the sustainability of liquidity, dividends, and repurchase plans.
- Developments in the Puerto Rico tax dispute and other litigation, including whether estimates, accruals, or potential outcomes change.
The independent auditor issued an unqualified opinion on the financial statements and reported effective internal control over financial reporting as of April 24, 2020.